Investors had high hopes for VIVUS' (NASDAQ: VVUS) new anti-obesity drug Qsymia, but the drug debuted to lackluster sales -- and it's taking a toll on VIVUS' share price. Now, VIVUS is shifting its focus -- marketing not to the doctors who will be prescribing Qsymia, but directly to patients by offering a free trial. Does this shift represent a fundamentally different marketing approach for the company, and more importantly for investors, will it work? Health care analysts Max Macaluso and Brenton Flynn discuss this news in the following video.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.